Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of recombinant human BLyS receptor–antibody fusion protein in primary Sjögren’s syndrome
CTR20191385Phase 2Completed
- Sponsor
- RemeGen
- Start
- Jul 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of atacicept in primary Sjögren's syndrome, sponsored by RemeGen. Started Jul 2019; status: completed.
02
Drugs
atacicept
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on CTR20191385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191385.